![2,8-dimethyl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole dihydrochloride](https://static.cymitquimica.com/cas-image/107178-28-dimethyl-2344a-59b-hexahydro-1h-pyrido-43-b-indole-dihydrochloride.png)
CAS: 33162-17-3 - 2,8-dimethyl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole dihydrochloride
Formule :C13H20Cl2N2
InChI :InChI=1S/C13H18N2.2ClH/c1-9-3-4-12-10(7-9)11-8-15(2)6-5-13(11)14-12;;/h3-4,7,11,13-14H,5-6,8H2,1-2H3;2*1H
Code InChI :InChIKey=XWLFAMANDIWUKH-UHFFFAOYSA-N
SMILES :Cl.C=1C=C2NC3CCN(C)CC3C2=CC1C
![2,8-Dimethyl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole dihydrochloride](https://static.cymitquimica.com/products/54/thumb/OR953929.jpg)
2,8-Dimethyl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole dihydrochloride
CAS :33162-17-3
Couleur et forme :
Solid
Masse moléculaire :
275.22g/mol
Ref: 54-OR953929
| 1g | 152,00 € | ||
| 5g | 448,00 € |
Livraison estimée en/au États-Unis, le mardi 26 novembre 2024
![2,8-dimethyl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole](https://static.cymitquimica.com/products/10/thumb/F425361.jpg)
![2,8-Dimethyl-2,3,4,4a,5,9b-hexahydro-1H-pyrido-[4,3-b]indole dihydrochloride](https://static.cymitquimica.com/products/3D/thumb/IBA16217.jpg)
2,8-Dimethyl-2,3,4,4a,5,9b-hexahydro-1H-pyrido-[4,3-b]indole dihydrochloride
CAS :33162-17-3
Dimebon is a drug that is used to treat Parkinson's disease and other neurological diseases. …
Formule :
C13H20Cl2N2
Degré de pureté :
Min. 95%
Masse moléculaire :
275.22 g/mol
Ref: 3D-IBA16217
| 250mg | 256,00 € | ||
| 2500mg | 1.017,00 € |
Livraison estimée en/au États-Unis, le mardi 7 janvier 2025
Carbidine
CAS :33162-17-3
Carbidine, a gamma-carboline derivative, is an atypical antipsychotic that modulates dopamine release and tyrosine hydroxylase …
Formule :
C13H20Cl2N2
Degré de pureté :
100%
Couleur et forme :
Solid
Masse moléculaire :
275.217
Ref: TM-T23854
| 5mg | 34,00 € | ||
| 10mg | 49,00 € | ||
| 25mg | 72,00 € | ||
| 50mg | 93,00 € | ||
| 100mg | 140,00 € | ||
| 200mg | 182,00 € |
Livraison estimée en/au États-Unis, le lundi 27 janvier 2025
